Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by Claridgeon Jun 12, 2019 8:55pm
145 Views
Post# 29820625

UHN neurosurgeon Dr. Zadeh on the latest in Glioblastoma

UHN neurosurgeon Dr. Zadeh on the latest in GlioblastomaFrom the one that plugged us to the first edition Neuro-Oncology Advances journal.

May 23, 2019

Q&A with UHN neurosurgeon Dr. Gelareh Zadeh on the latest in Glioblastoma research


So UHN is clearly pushing R&D on this indication.  It bodes well for us.


________________

Claridge - (6/2/2019 2:59:29 PM) 

RE:More on the Neuro-Oncology Advances journal

And where does the inaugural Editor-in-Chief (EIC) of this new journal Neuro-Oncology Advances (NOA) journal comes from?  UHN!


Gelareh Zadeh



Gelareh Zadeh | UHN Research

 


We have such an amazing partner in UHN!

____________________

Claridge - (6/2/2019 2:38:19 PM) 

More on the Neuro-Oncology Advances journal

Very interesting to make the premiere of NOA, considering the following:


Neuro-Oncology Advances: Hot Off the Press


Neuro-Oncology AdvancesVolume 1, Issue 1, May-December 2019, vdz002,https://doi.org/10.1093/noajnl/vdz002
Published:
   
20 May 2019

It is an honour and privilege to be the inaugural Editor-in-Chief (EIC) of the new journal Neuro-Oncology Advances (NOA)Neuro-Oncology Advances is the first open-access journal that is also an official journal of the Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO).

The creation of this new journal has been a team sport, and culmination of hours of dedication and planning by various stakeholders. I am fortunate to be joined by a team of executive and associate Editors who bring the necessary experience and expertise to shape the path for this new journal. Amongst the many individuals, a few deserve special recognition, including the past president of SNO, Nino Chiocca, current president and former Editor-in-Chief of Neuro-Oncology Patrick Wen, together with current-EIC of Neuro-oncology, Ken Aldape, all of whom have been instrumental in making the vision for this new journal a reality. The journal is also a true partnership with EANO, represented by the past and current presidents, Wolfgang Wick and Martin van den Bent. Chas Haynes has with precise attention to details ensured a smooth execution in partnership with Oxford University Press.

Neuro-Oncology Advances was conceptualized to meet an area of unmet need and work seamlessly with Neuro-Oncology to complement the vision, mandate and above all quality of the content material published. The field of neuro-oncology has experienced a tremendous growth in the past decade, with increasing interest in research and clinical care delivery for patients with brain tumours. There is a clear exponential rise in membership to the field and expertise being built throughout disciplines to advance neuro-oncology. Equally, the Neuro-Oncology has benefitted from this growth together with leadership to reach record high submissions and most importantly an impact factor that is competitive with reputable journals in the broader area of cancer research at 9.38. We are witnessing a transformation of the field of neuro-oncology; therefore it is timely to introduce an open-access journal. NOA will ensure that research and discoveries in the field is retained within the broader readership and community of the neuro-oncology field.

NOA will serve to disseminate and raise awareness of the sound and competitive investigative work that is being done in the field that complements and advances the scope of Neuro-Oncology. NOA allows a mechanism to increase presence in areas of CNS oncology that are outside of the traditionally accepted mandates of Neuro-Oncology. NOA will commit to publications in the area of brain metastasis, as this is an area with a fast-pace changing landscape of treatment paradigms that demands a multi-disciplinary focus and recognition of the importance in advances. NOA will also include primary CNS treatment and the associated neurological complications and side effects of brain metastases. Similarly, there is a large momentum being built around research in meningiomas and other non-malignant tumours. NOA will place a stronger emphasis on non-malignant brain tumours, such as meningiomas, schwannomas, pituitary tumours, spinal and peripheral nerve tumours and many others that have traditionally not been included in the main mandate of Neuro-Oncology. Additionally, NOA will promote technological advances and innovation in surgery, radiation therapy delivery and neuro-imaging.

NOA is an official partnership between SNO and EANO, where the leadership and direction is set jointly by the two societies. I am grateful to the support and recognition that Wolfgang Wick, as the deputy and executive editor representing EANO, will bring to the journal.

I hope that NOA will become an invaluable resource for the field, that the readership and scientific community will endorse and patients will find useful. Furthermore, I hope that the excitement that I, the executive team and associate editors share for this journal will be adopted by you, to encourage submission of your work for publication.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model 
 

Bullboard Posts